undefined undefined undefined

Therapeutic advances in cardiometabolic HFpEF: pharmacotherapy and lifestyle intervention

Event: ESC Congress 2025

Topic: Cardiovascular Pharmacotherapy

Session type: Symposium

Access

Like

Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression

Event: ESC Congress 2025

Topic: Heart Failure

Session type: Moderated ePosters

Access

Like

The floor is yours: bring your questions on management of cardiovascular-kidney-metabolic syndrome

Event: ESC Congress 2025

Topic: Cardiovascular Pharmacotherapy

Session type: Bring your Questions

Access

Like

What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Event: ESC Congress 2025

Topic: Antidiabetic Pharmacotherapy

Session type: Abstract Sessions

Access

Like

Mechanisms of cardiomyopathy and heart failure: from fibroblast dynamics to metabolic remodelling

Event: ESC Congress 2025

Topic: Heart Failure

Session type: Moderated ePosters

Access

Like

The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart

Event: HFA Winter Research Meeting on Translational Heart Failure 2025

Topic: Drugs, Drug Targets

Session type: Symposium

Access

Like

Chronic heart failure - epidemiology, prognosis, outcome 7

Event: Heart Failure 2023

Topic: Epidemiology, Prognosis, Outcome

Session type: Moderated ePosters

Access

Like

Valvular heart disease

Event: Heart Failure 2023

Topic: Valvular Heart Disease

Session type: Moderated ePosters

Access

Like

Multi-omics for personalised medicine

Event: HFA Winter Research Meeting on Translational Heart Failure 2023

Topic: Cardiomyopathies

Session type: Symposium

Access

Like

Pathomechanisms of heart failure with preserved ejection fraction

Event: ESC Congress 2022

Topic: Heart Failure

Session type: Moderated ePosters

Access

Like

undefined undefined undefined

Contributor content

Therapeutic advances in cardiometabolic HFpEF: pharmacotherapy and lifestyle intervention

Metabolic, immune, and cellular drivers of HFpEF pathogenesis and progression

The floor is yours: bring your questions on management of cardiovascular-kidney-metabolic syndrome

What's new for GLP-1 agonist and SGLT2 inhibitor cardiovascular pharmacotherapy?

Mechanisms of cardiomyopathy and heart failure: from fibroblast dynamics to metabolic remodelling

The cardiometabolic syndrome and extracardiac drug effects beneficial to the heart

Chronic heart failure - epidemiology, prognosis, outcome 7

Valvular heart disease

Multi-omics for personalised medicine

Pathomechanisms of heart failure with preserved ejection fraction

ESC 365 is supported by